[{"address1": "620 Memorial Drive", "address2": "5th Floor", "city": "Cambridge", "state": "MA", "zip": "02139", "country": "United States", "phone": "617 577 0300", "website": "https://www.evelobio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 66, "companyOfficers": [{"maxAge": 1, "name": "Mr. Craig R. Jalbert CIRA", "age": 61, "title": "President, Secretary, Principal Executive, Financial and Accounting Officer & Director", "yearBorn": 1962, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Chun  Zhang Ph.D.", "title": "Chief Technical Operations & Quality Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark  Bodmer Ph.D.", "age": 65, "title": "Chief Scientific Officer and President of Research & Development", "yearBorn": 1958, "fiscalYear": 2017, "totalPay": 668800, "exercisedValue": 0, "unexercisedValue": 3169478}, {"maxAge": 1, "name": "Ms. Jessica  Cotrone", "title": "VP & Head of Communications", "fiscalYear": 2017, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leslie  Wardwell-Scott Ph.D.", "title": "VP and Head of Corporate Development & Strategic Integration", "fiscalYear": 2017, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrea  Itano Ph.D.", "title": "Head of Research", "fiscalYear": 2017, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Duncan  McHale M.D., MBBS, Ph.D.", "age": 56, "title": "Chief Medical Officer", "yearBorn": 1967, "fiscalYear": 2017, "totalPay": 661968, "exercisedValue": 0, "unexercisedValue": 1128160}, {"maxAge": 1, "name": "Mr. Douglas  Maslin", "title": "Senior Director & Immunology Clinical Lead", "fiscalYear": 2017, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1514678400, "maxAge": 86400, "priceHint": 4, "previousClose": 0.0526, "open": 0.06274, "dayLow": 0.055, "dayHigh": 0.0679, "regularMarketPreviousClose": 0.0526, "regularMarketOpen": 0.06274, "regularMarketDayLow": 0.055, "regularMarketDayHigh": 0.0679, "beta": 2.047, "forwardPE": -0.033513512, "volume": 74634, "regularMarketVolume": 74634, "averageVolume": 133895, "averageVolume10days": 78390, "averageDailyVolume10Day": 78390, "bidSize": 2900, "askSize": 1000, "marketCap": 1176933, "fiftyTwoWeekLow": 0.028, "fiftyTwoWeekHigh": 13.93, "fiftyDayAverage": 0.05394, "twoHundredDayAverage": 2.820525, "currency": "USD", "enterpriseValue": 17859720, "floatShares": 16689345, "sharesOutstanding": 18982800, "sharesShort": 196993, "sharesShortPriorMonth": 156444, "sharesShortPreviousMonthDate": 1698710400, "dateShortInterest": 1701302400, "sharesPercentSharesOut": 0.0104, "heldPercentInsiders": 0.00161, "heldPercentInstitutions": 0.13239999, "shortRatio": 0.12, "shortPercentOfFloat": 0.0222, "impliedSharesOutstanding": 18982800, "bookValue": -1.417, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -82349000, "trailingEps": -15.64, "forwardEps": -1.85, "lastSplitFactor": "1:20", "lastSplitDate": 1688083200, "enterpriseToEbitda": -0.256, "52WeekChange": -0.9916216, "SandP52WeekChange": 0.3288405, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "EVLO", "underlyingSymbol": "EVLO", "shortName": "Evelo Biosciences, Inc.", "longName": "Evelo Biosciences, Inc.", "firstTradeDateEpochUtc": 1525786200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "fb56bcc1-036c-3103-a1ef-4deb82721e11", "messageBoardId": "finmb_331329033", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.062, "targetHighPrice": 10.0, "targetLowPrice": 10.0, "targetMeanPrice": 10.0, "targetMedianPrice": 10.0, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 1, "totalCash": 17262000, "totalCashPerShare": 0.912, "ebitda": -69674000, "totalDebt": 33948000, "quickRatio": 0.434, "currentRatio": 0.476, "returnOnAssets": -0.83247, "freeCashflow": -43313248, "operatingCashflow": -73701000, "financialCurrency": "USD", "trailingPegRatio": null}]